Loading clinical trials...

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris | Clinical Trials | Clareo Health

COMPLETEDPHASE2

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

NCT02888236•LEO Pharma

View on ClinicalTrials.gov

Summary

A study of LEO 32731 in the treatment of psoriasis vulgaris

Detailed Description

This is an investigation of the efficacy of LEO 32731 30 mg as compared to placebo after 16 weeks of oral treatment of psoriasis vulgaris

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Signed and dated informed consent
•Aged between 18 years and 65.
•Males or females of non-childbearing potential.
•Clinical diagnosis of psoriasis vulgaris with or without psoriatic arthritis
•Have moderate to severe psoriasis vulgaris
•Candidates of systemic anti-psoriatic treatment and/or phototherapy

Exclusion Criteria

•Subjects with therapy resistant psoriasis
•Previously exposed to apremilast
•Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris
•Systemic treatment with all other therapies (other than biologics) with a possible effect on psoriasis vulgaris

Locations (1)

Charité Universitätsmedizin Berlin, Dept. of Dermatology

Berlin, Germany

Key Dates

Start Date

September 1, 2016

Primary Completion Date

June 20, 2017

Completion Date

July 6, 2017

Last Updated

August 28, 2017

Enrollment

ACTUAL participants

Conditions

Psoriasis Vulgaris

Interventions

LEO 32731

DRUG

LEO 32731 Placebo

DRUG

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

NCT04080635

Psoriasis Vulgaris

View study

COMPLETEDPHASE4

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

NCT04340076

PsoriasisPsoriasis Vulgaris

View study

WITHDRAWNNA

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 28, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Inclusion Criteria

Exclusion Criteria

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

The Mediterranean Diet and Time-Restricted Eating Dietary Interventions for Psoriasis Study